Elke Geens

Ikazia Ziekenhuis — Netherlands

Medicine · Health Sciences

7h-index386citations19works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Rheumatoid Arthritis Research and Therapies(15), Autoimmune and Inflammatory Disorders Research(9), Systemic Lupus Erythematosus Research(8), Respiratory viral infections research(5), Chronic Lymphocytic Leukemia Research(4)

Publications19 total

Generation of a T cell receptor, cytokine and cell repertoire synovial fluid atlas to define commonalities and dissimilarities between arthritic diseases through systems immunology approaches
2025· 4 citedOpen Access
POS0335 DECODING THE T-CELL RECEPTOR REPERTOIRE IN CHRONIC ARTHRITIS ACROSS DIFFERENT AGES, DISEASE GROUPS, AND T-CELL SUBSETS
Annals of the Rheumatic Diseases·2024
Blood transcriptomics to facilitate diagnosis and stratification in pediatric rheumatic diseases – a proof of concept study
Pediatric Rheumatology·2022· 7 citedOpen Access
Additional file 2 of Blood transcriptomics to facilitate diagnosis and stratification in pediatric rheumatic diseases – a proof of concept study
Figshare·2022Open Access
Additional file 6 of Blood transcriptomics to facilitate diagnosis and stratification in pediatric rheumatic diseases – a proof of concept study
Figshare·2022Open Access
Additional file 4 of Blood transcriptomics to facilitate diagnosis and stratification in pediatric rheumatic diseases – a proof of concept study
Figshare·2022Open Access
Additional file 3 of Blood transcriptomics to facilitate diagnosis and stratification in pediatric rheumatic diseases – a proof of concept study
Figshare·2022Open Access
Additional file 5 of Blood transcriptomics to facilitate diagnosis and stratification in pediatric rheumatic diseases – a proof of concept study
Figshare·2022Open Access
Tapering of Etanercept is feasible in patients with Rheumatoid Arthritis in sustained remission: a pragmatic randomized controlled trial
Scandinavian Journal of Rheumatology·2021· 14 citedOpen Access
SAT0135 MAINTAINING REMISSION IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS WHILE TAPERING ETANERCEPT: AN INSIGHT IN THE TAPERA TRIAL
Annals of the Rheumatic Diseases·2019· 1 citedOpen Access
Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA
Lara D. Veeken·2019· 58 citedOpen Access
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial
Annals of the Rheumatic Diseases·2016· 114 cited
THU0117 Low-Risk Patients Also Benefit from Remission Induction Treatment in Early Rheumatoid Arthritis: Week 52 Results from the Carera Trial
Annals of the Rheumatic Diseases·2015· 2 cited
OP0180 Remission Induction with Dmard Combinations and Glucocorticoids is not Superior to Remission Induction with MTX Monotherapy and Glucocorticoids: Week 52 Results of the High-Risk Group from the Carera Trial
Annals of the Rheumatic Diseases·2015· 3 cited
Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial
Arthritis Research & Therapy·2015· 42 citedOpen Access
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial
Annals of the Rheumatic Diseases·2014· 124 citedOpen Access
THU0137 Associated with A Glucocorticoid Bridging Scheme, Methotrexate is as Effective Alone as in Combination with Other DMARDS for Early Rheumatoid Arthritis, with Fewer Reported Side Effects: 16 Weeks Remission Induction Data from the Carera Trial
Annals of the Rheumatic Diseases·2014· 8 cited
THU0121 Comparison of MTX Therapy with or without A Moderate Dose Glucocorticoid Bridging Scheme in Early Rheumatoid Arthritis Patients Lacking Classical Poor Prognostic Markers: Week 16 Results from the Randomized Multicenter Carera Trial
Annals of the Rheumatic Diseases·2014· 4 cited
Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria
Lara D. Veeken·2008· 5 citedOpen Access

Frequent Co-authors

Patrick Verschueren(12), Diederik De Cock(10), C. Langenaken(10), V. Taelman(10), Johan Joly(10), René Westhovens(10), Piet Geusens(9), J. Vanhoof(9), Luk Corluy(8), Rik Joos(8), F. Raeman(8), K. Vandevyvere(8), Anne Durnez(8), J Remans(8), Bert Vander Cruyssen(8), E. Van Essche(8), A. Sileghem(8), G. De Brabanter(8), Kristien Van der Elst(8), Esther Bartholomeus(8)